BRIEF—Alvotech and STADA launch Hukyndra in Switzerland

Adding to the roll out of their biosimilar to AbbVie’s mega blockbuster drug Humira (adalimumab), Icelandic firm Alvotech and German partner STADA Arzneimittel today announced the launch of Hukyndra in Switzerland.

Marketed by STADA subsidiary Spirig HealthCare in Switzerland, Hukyndra is available in 80mg/0.8mL and 40mg/0.4mL presentations in a safety device for self-administration and 40mg/0.4mL in a pre-filled auto-inject pen, designed with the ease of patients in mind, the companies stated.

Under the terms of a European patent resolution announced in April, AbbVie has granted Alvotech a non-exclusive, royalty bearing license to AbbVie’s intellectual property relating to Humira in Europe and in selected markets outside of Europe.

In  November 2021, STADA received approval from the European Commission for Hukyndra, in the 27 EU member states, plus Norway, Iceland and Lichtenstein.

Hukyndra has already launched in Austria, Estonia, France, Finland, Germany, Lithuania, Slovakia and Sweden.